Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations.

scientific article published on 07 November 2018

+ JoinSee the latest ↓

01Latest 02Today 03Journal 04About

The journal

Open the journal →

The conversation starts in the journal — be the first to post.

About Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations

Everything about Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations →

Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations — scientific article published on 07 November 2018